Click here to start your patients
on the path to just 2 DOSES A YEAR
- For US Healthcare Professionals Only
*The study was conducted in 26 countries, excluding the United States.
†All patients diagnosed 1 to 5 years previously with ≥2 relapses requiring hospitalization.
‡Time to relapse was significantly longer in patients treated with INVEGA SUSTENNA® (P=0.019; hazard ratio 1.5; CI=1.1-2.2). 85th percentile for time to relapse was 469 days.
§At 24 months, 52 (14.8%) patients on INVEGA SUSTENNA® experienced a relapse vs 76 (20.9%) in the oral antipsychotic group.
Primary endpoint: Significantly longer time to relapse in patients receiving INVEGA SUSTENNA® vs oral antipsychotics (P=0.019; HR=1.5, 95% CI=1.1-2.2)
Secondary endpoint: Significantly fewer patients relapsed in the INVEGA SUSTENNA® vs oral antipsychotics arm§(14.8% and 20.9%; P=0.032)
Patients randomized (1:1) to INVEGA SUSTENNA® or oral treatment arms entered a 2-week initial acute oral treatment phase
ER=extended-release; PANSS=Positive and Negative Syndrome Scale; LAI=long-acting injectable; CGI=Clinical Global Impressions scale; QD=every day.
*The study was conducted in 26 countries, excluding the United States.
†All patients diagnosed 1 to 5 years previously with ≥2 relapses requiring hospitalization.
‡Time to relapse was significantly longer in patients treated with INVEGA SUSTENNA® (P=0.019; hazard ratio 1.5; CI=1.1-2.2). 85th percentile for time to relapse was 469 days.
§At 24 months, 52 (14.8%) patients on INVEGA SUSTENNA® experienced a relapse vs 76 (20.9%) in the oral antipsychotic group.
||Relapse defined by any of the following: psychiatric hospitalization; increase in the level of psychiatric care and an increase of 25% from baseline in PANSS total score (or an increase of 10 points if baseline score ≤40); deliberate self-injury; suicidal or homicidal ideation; violent behavior resulting in injury to another person or property damage; substantial clinical deterioration; required dose of antipsychotic exceeds the maximum approved dose.